Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 85-2786970 (I.R.S. Employer Identification No.) Re ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Chairman of the Board and Interim CEO Kevin Herde - Chief Financial Officer Becky Buzzeo - Chief Commercial Officer Trey Martin - President Biologics Safety Testing Conference Call Participants Conor McNamara - RBC Capital Markets Catherine Schulte - Baird Matt Sykes - Goldman Sachs Dan Leonard - Credit Suisse Dan Arias - Stifel J ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 85-2786970 (I.R.S. Employer Identification No.) 9 ...

2018 $619K 2020 $1.3M Maravai Sales Catalyzing the Customer Journey to Enable the Miracles of Science 1. AAE = Antibody Affinity Extraction™ ©2023 Maravai LifeSciences. This document and its contents are confidential and proprietary and are not to be shared or redistributed without express consent. 4 Serving high-growth end markets Maravai Products Offered | --- | --- | --- | --- | --- | --- | --- | |----------------|---------------|----------------------------------|----------------------------------|----- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) | Delaware | 85-2786970 | | --- | --- | | (State or other juris ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2022 Earnings Conference Call February 22, 2023 5:00 PM ET Company Participants Debra Hart - Head of Investor Relations Carl Hull - Interim Chief Executive Officer Kevin Herde - Chief Financial Officer Trey Martin - President of Biologic Safety Testing Becky Buzzeo - Chief Commercial Officer Conference Call Participants Dan Leonard - Credit Suisse Matthew Sykes - Goldman Sachs Daniel Arias - Stifel Catherine Schulte - Robert W. Baird Tejas Savant - Mor ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 85-2786970 (I.R.S. Employer Identification No ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q3 2022 Results Conference Call November 2, 2022 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Interim Chief Executive Officer Kevin Herde - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley John Sourbeer - UBS Paul Knight - KeyBanc Madeline Mollman - William Blair Michael Ryskin - Bank of America Dan Arias - Stifel Dan Leonard - Credit Suisse Brandon Couillard - Jefferies Operator Greeting ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Deb Hart - Head of Investor Relations Carl Hull - Chief Executive Officer Kevin Herde - Chief Financial Officer Conference Call Participants Max Smock - William Blair & Company Matthew Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Paul Knight - KeyBanc Capital Markets Inc. Michael Ryskin - Bank of America Brandon Couillard - Jefferies Group LLC John Sourbeer - UBS Group AG ...

Q2 2022 Financial Results (Nasdaq: MRVI) August 4, 2022 eSciences Today's Agenda Welcome Deb Hart, Head of Investor Relations 01 Financial Results & Guidance Kevin Herde, Chief Financial Officer 02 Business Highlights & Update Carl Hull, Chief Executive Officer 03 04 Q&A Session Carl Hull, Chief Executive Officer Kevin Herde, Chief Financial Officer 2 Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains, and our officers and representatives may from time-to-time make, ...